Loading Events

« All Events

Bone, Reproductive and Urologic Drugs Advisory Committee

January 16, 2019

The committee will discuss biologics license application 761062, romosozumab injection, submitted by Amgen, for the proposed indication of treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant of other available osteoporosis therapy.

Details

Date:
January 16, 2019
Event Category: